Posaconazole attenuates arsenic trioxide toxicity and enhances safety and efficacy while reducing invasion and metastasis in non-small-cell lung cancer

Key Points

• Posaconazole significantly reduces arsenic trioxide toxicity, enhancing overall treatment safety.
• The study found that posaconazole decreased invasion and metastasis, promoting better control over cancer progression.
• Analysis demonstrated improved treatment efficacy, leading to favorable outcomes in non-small-cell lung cancer models.
• Combining posaconazole with arsenic trioxide may provide a new strategy, emphasizing the need for clinical trials.